Dana-Farber Cancer Institute Harvard University — Boston, Massachusetts

Dana-Farber Cancer Institute Harvard University is a clinical research site located in Boston, Massachusetts, United States 02215-6024.

Crixeo Health Trust Score: 63/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute Harvard University has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma.

Sponsors: University of California, San Francisco, Gruppo Italiano Malattie EMatologiche dell'Adulto.

Sponsor Feasibility Report

Trust Score: 63/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute Harvard University?

Dana-Farber Cancer Institute Harvard University has a Crixeo Trust Score of 63/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute Harvard University conducted?

Dana-Farber Cancer Institute Harvard University has 2 clinical trials on record, with 1 currently active. Their work covers Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma.

Is Dana-Farber Cancer Institute Harvard University accredited by Crixeo Health?

Dana-Farber Cancer Institute Harvard University has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber Cancer Institute Harvard University?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.